. "Appendix A: Pandemic Influenza: Assessing Capabilities for Prevention and Response." The Threat of Pandemic Influenza: Are We Ready? Workshop Summary. Washington, DC: The National Academies Press, 2005.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
The Threat of Pandemic Influenza: Are We Ready? - Workshop Summary
Session III:Obstacles and Opportunities for Optimal Preparedness
Moderator: Gary Roselle, MD,Program Director for Infectious Diseases, Department of Veterans Affairs Central Office
1:00–1:20
Partnering with the Private Medical System
Gordon Grundy, MD, Regional Medical Director, Aetna Inc.
1:20–1:35
Discussion
1:35–1:55
Vaccine Development and Production Issues
Philip Hosbach, Vice President of New Products and Immunization Policy, Aventis Pasteur SA
1:55–2:10
Discussion
2:10–2:30
Ensuring an Adequate Stockpile of Antivirals
Paul Brown, PhD, Global Task Force Leader for Tamiflu™ Pandemic Planning, F. Hoffmann La-Roche, Switzerland
2:30–2:45
Discussion
2:45–3:05
Chasing the Elusive Virus: Preparing for the Future by Examining the Past
Jeffery K. Taubenberger, MD, PhD, Chair, Department of Molecular Pathology, Armed Forces Institute of Pathology, U.S. Department of Defense
3:05–3:20
Discussion
3:20
Break
Session IV:Panel Discussion—Innovating Past Barriers
Moderator: Joshua Lederberg, PhD,Nobel Laureate, Sackler Foundation Scholar, Rockefeller University
3:30–3:45
Strategies for Control of Influenza by Targeting Broadly Conserved Viral Features
Suzanne Epstein, PhD, Center for Biologics Evaluation and Research, Food and Drug Administration
3:45–4:10
Mathematical Modeling: Containing Pandemic Influenza with Vaccines and Antivirals
Ira Longini, MD, Rollins School of Public Health, Emory University, Atlanta, GA
March Lipsitch, PhD, Harvard School of Public Health, Boston, MA
